An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

Phase 4

Completed

• Conditions: Glaucoma; Ocular Hypertension

• Registration Number: NCT00329095
• Lead Sponsor: Robin, Alan L., M.D.

Brief Summary

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Detailed Description

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Study Timeline

• Study Start: 2005-12
• Study Completion: 2006-04
• Status Verified: 2006-05
• Study First Submitted: 2006-05-19
• Study First Submitted QC: 2006-05-22
• Last Update Submitted: 2006-05-22
• Study First Posted: 2006-05-24
• Last Update Posted: 2006-05-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Currently using one or two topical ocular hypotensive medications

Exclusion Criteria

• Hypersensitivity to any component of medication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Compliance.